MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Icosabutate

CAS No. : 1253909-57-7

MCE 国际站：Icosabutate

产品活性：Icosabutate 是一种具有口服活性的 ω-3多不饱和脂肪酸，是二十碳五烯酸的衍生物 (EPA derivative)。Icosabutate 克服了未经修饰的 EPA 对肝脏靶向的缺点，可改善了胰岛素敏感性，肝炎和纤维化。Icosabutate 具有良好的耐受性，可有效降低持续性高甘油三酯血症中的非高密度脂蛋白胆固醇 (non-HDL-C) 水平。

研究领域：Others

作用靶点：Others

In Vivo: Icosabutate (oral gavage; 100 mg/kg; once) accounts for the much higher flow rate of portal vein plasma (522 mL/h) versus mesenteric lymph (0.5 mL/h), that data demonstate that icosabutate is almost entirely taken up through the portal vein (>99%) with only a small fraction of icosabutate being absorbed through the lymphatic pathway in 8‐week old male Wistar rats.
Icosabutate ([14‐C]‐icosabutate; oral gavage; 100 mg/kg; once) shows that peak concentrations of radioactivity in most tissues at 4‐8 hours after the dose (except the gastrointestinal tract) with highest concentrations in the liver and kidney, most other tissues contain levels of radioactivity below that in plasma in male albino Wistar rats.
Icosabutate (diet administration; 135 mg/kg/day; 5 weeks) markedly improved glucose tolerance after an oral glucose load, significantly reduces AUC (0‐120 minutes) by 60% without affecting body weight, decrease plasma alanine aminotransferase (ALT) levels improves glucose metabolism by a significant decrease in blood glucose, blood hemoglobin A1c, plasma insulin, and HOMA‐IR (-50%, -47%, -76% and -87%, respectively) in mice.
Icosabutate (oral adminstration; 112 mg/kg/day; 20 weeks) prevents microvesicular steatosis (-35%) and hepatocellular hypertrophy (-82%), but not macrovesicular steatosis. After 20 weeks of treatment, despite comparable decreases in hepatic inflammatory cell aggregates, only icosabutate reduced hepatic collagen content.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Anti-diabetic Compound Library  |  Lipid Compound Library  |  Orally Active Compound Library  |  Antitumor agent-67  |  Catechin 7-O-β-D-glucopyranoside  |  Carbobenzoxyproline  |  ATR-IN-9  |  TBTDC  |  Peucenin 7-O-methyl ether  |  6-Hydroxy-4-methylcoumarin  |  AMT-NHS  |  Nylidrin hydrochloride  |  D-(+)-Fucose  |  OVA Peptide (323-339)  |  Secretin (swine)  |  Bletilloside A  |  Transcriptional Intermediary Factor 2 (TIF2) (740-753)  |  Pep-1 (uncapped)  |  Aspochalasin M  |  Dihydrofuran-3(2H)-one  |  2,6-Difluoropyridine  |  BPK-29 hydrochloride  |  pppApG  |  MEIS-IN-2  |  2′-O-Methyl-8-methyl guanosine  |  Altertoxin I  |  Lithospermoside  |  Acitazanolast  |  FLAG peptide  |  [Des-Tyr1]-Met-Enkephalin  |  α-Carotene  |  myo-Inositol trispyrophosphate hexa-triethylamine  |  Myt1-IN-2

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

货号: HY-121212

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。